Neurogene Inc.
NGNE
$15.22
-$0.29-1.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -97.36% | -106.91% | -4.50% | 2.70% | 21.59% |
| Total Depreciation and Amortization | -3.63% | -1.52% | -2.90% | 8.42% | 5.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 162.95% | 150.46% | -632.30% | -613.78% | -780.49% |
| Change in Net Operating Assets | 92.37% | -48.17% | -1,109.10% | -3,872.87% | -145.85% |
| Cash from Operations | -17.15% | -37.30% | -57.02% | -50.53% | -17.91% |
| Capital Expenditure | -326.61% | -151.71% | -97.59% | -120.72% | 71.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -667.77% | -2,589.06% | -- | -- | -- |
| Cash from Investing | -460.14% | -588.59% | 867.47% | 9,730.33% | 4,530.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -60.00% | -79.31% | -113.64% | -275.00% | -483.33% |
| Issuance of Common Stock | 27,732.85% | 113,748.21% | 452.56% | 448.22% | 278.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -107.73% | 4,544.77% | 85,401.00% | -- |
| Cash from Financing | 122.01% | 99.03% | 5,049.72% | 125,024.64% | 157.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -196.87% | -117.68% | 145.72% | 218.47% | 546.89% |